Company Directory - REGENXBIO Inc.
Company Details - REGENXBIO Inc.
REGENXBIO Inc.
REGENXBIO Inc. is a biotechnology company focused on developing gene therapies for genetic diseases.
CCI Score
CCI Score: REGENXBIO Inc.
-21.31
0.01%
Latest Event
REGENXBIO Lobbying Activity Revealed via OpenSecrets
REGENXBIO Inc.'s lobbying profile on OpenSecrets demonstrates active engagement in lobbying efforts. The disclosed lobbying activity raises concerns over potential undue influence on policy and democratic accountability, reflecting patterns that could align with broader corporate complicity in authoritarian practices.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ACCOMPLICE
REGENXBIO Inc. is currently rated as an Accomplice.
Latest Events
- FEB192025
REGENXBIO Inc.'s lobbying profile on OpenSecrets demonstrates active engagement in lobbying efforts. The disclosed lobbying activity raises concerns over potential undue influence on policy and democratic accountability, reflecting patterns that could align with broader corporate complicity in authoritarian practices.
-40
Political Contributions and Lobbying Efforts
March 26
Data from the OpenSecrets profile indicates that REGENXBIO actively employs multiple lobbying firms to advance its interests. From an anti-fascist perspective, such political spending and opaque influence can contribute to the erosion of democratic institutions, aligning with authoritarian tendencies in corporate behavior.
- JAN012024
Based on data from OpenSecrets, REGENXBIO has an established history of lobbying activities. Although it has not reported lobbying on specific bills in 2024, its ongoing engagement in the political process raises questions about corporate influence over policy, a concern from an anti-fascist perspective.
-10
Political Contributions and Lobbying Efforts
March 26
REGENXBIO's profile on OpenSecrets reveals that the company engages in lobbying activities. While it has not reported lobbying on specific bills in 2024, the very act of lobbying indicates corporate efforts to influence public policy. From an anti-fascist and progressive perspective, such political contributions and lobbying efforts can undermine democratic accountability and contribute to a broader pattern of corporate interference in policymaking.
- JAN012024
REGENXBIO Inc. reported spending $15,000 on lobbying efforts in 2024, reflecting an attempt to influence policy areas that potentially benefit its corporate interests. Although the sum is relatively modest, the use of corporate funds for political lobbying raises concerns about aligning with policies that may undermine broader democratic accountability.
-20
Political Contributions and Lobbying Efforts
March 26
The reported $15,000 in lobbying expenses for 2024 indicates that REGENXBIO is engaging in political influence activities. While the expenditure may be small compared to industry giants, any corporate lobbying efforts can be viewed as an attempt to shape policy in favor of corporate interests. In a context where corporate political spending can support authoritarian policy shifts, this activity is assessed negatively.
- JAN012021
REGENXBIO spent $235,000 on lobbying activities in 2021, indicating its active engagement in political influence. This involvement raises concerns from an anti-fascist perspective, as corporate lobbying can undermine democratic accountability and support policy outcomes that might favor authoritarian agendas.
-30
Political Contributions and Lobbying Efforts
March 26
REGENXBIO's expenditure of $235,000 on lobbying in 2021, as detailed by OpenSecrets, reflects the company's willingness to use financial influence to sway political outcomes. From an anti-fascist perspective, such political contributions can assist in undermining democratic accountability and potentially facilitate authoritarian policymaking.
Alternatives
Seattle, United States
-23.78
Abbott Park, United States
-41.78
Corporation
35.43
Zug, Switzerland
22.95
Cambridge, United States
-13.08
Corporation
45.62
Corporation
11.88
Corporation
0.00
Corporation
0.00
Corporation
0.00
Industries
- 325414
- Biological Product (except Diagnostic) Manufacturing
- 541714
- Research and Development in Biotechnology (except Nanobiotechnology)
- 621511
- Medical Laboratories